Canada Pension Plan Investment Board purchased a new position in Caris Life Sciences, Inc. (NASDAQ:CAI – Free Report) in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 1,374,952 shares of the company’s stock, valued at approximately $24,502,000.
Other institutional investors and hedge funds have also recently modified their holdings of the company. Global Retirement Partners LLC increased its holdings in shares of Caris Life Sciences by 99,900.0% in the fourth quarter. Global Retirement Partners LLC now owns 1,000 shares of the company’s stock worth $27,000 after buying an additional 999 shares during the period. PNC Financial Services Group Inc. boosted its holdings in Caris Life Sciences by 839.4% during the 1st quarter. PNC Financial Services Group Inc. now owns 1,644 shares of the company’s stock valued at $29,000 after acquiring an additional 1,469 shares during the period. Fifth Third Bancorp bought a new position in Caris Life Sciences during the 1st quarter worth approximately $31,000. Sterling Capital Management LLC increased its stake in Caris Life Sciences by 128.3% in the 1st quarter. Sterling Capital Management LLC now owns 1,927 shares of the company’s stock worth $34,000 after purchasing an additional 1,083 shares during the period. Finally, Trifecta Capital Advisors LLC bought a new stake in Caris Life Sciences in the second quarter valued at approximately $37,000.
Caris Life Sciences Stock Down 2.8%
Shares of Caris Life Sciences stock opened at $25.63 on Friday. The company has a current ratio of 5.53, a quick ratio of 4.88 and a debt-to-equity ratio of 0.66. Caris Life Sciences, Inc. has a 12-month low of $14.19 and a 12-month high of $39.18. The company has a market cap of $7.24 billion, a P/E ratio of 71.19 and a beta of 0.68. The company’s fifty day simple moving average is $19.27 and its two-hundred day simple moving average is $18.72.
Wall Street Analyst Weigh In
A number of equities research analysts have issued reports on CAI shares. Citigroup cut their price target on shares of Caris Life Sciences from $35.00 to $28.00 and set a “buy” rating on the stock in a report on Friday, May 8th. Weiss Ratings raised shares of Caris Life Sciences from a “sell (d-)” rating to a “sell (d)” rating in a research note on Friday, August 21st. Evercore reissued an “outperform” rating and issued a $26.00 target price on shares of Caris Life Sciences in a research note on Thursday, August 6th. Robert W. Baird set a $22.00 price target on Caris Life Sciences in a report on Friday, May 8th. Finally, Wall Street Zen raised Caris Life Sciences from a “sell” rating to a “hold” rating in a research report on Sunday, August 16th. Seven investment analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Caris Life Sciences currently has a consensus rating of “Moderate Buy” and a consensus target price of $26.33.
Get Our Latest Stock Analysis on Caris Life Sciences
Caris Life Sciences Company Profile
Caris Life Sciences (NASDAQ: CAI) is a molecular science company focused on advancing precision medicine in oncology. The company develops and delivers comprehensive molecular profiling services designed to identify actionable biomarkers across DNA, RNA and protein modalities. Its clinical services are intended to support oncologists in treatment decision-making by matching patients to targeted therapies, immunotherapies and relevant clinical trials based on tumor biology.
Caris provides laboratory-based diagnostic testing and related interpretive reports, combining high-throughput sequencing and other molecular technologies with bioinformatic analysis.
Featured Articles
- Five stocks we like better than Caris Life Sciences
- 3 Financial Stocks Positioned for the Fed’s Next Move After Jackson Hole
- IREN’s AI Pivot Looks Real, But the Market Wanted a Faster Payoff After Earnings
- Boeing’s $131B F-15 Win: Mach 1 Momentum or Just Altitude?
- Okta Stock Surges 29%—Is $200 the Next Stop?
Want to see what other hedge funds are holding CAI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Caris Life Sciences, Inc. (NASDAQ:CAI – Free Report).
Receive News & Ratings for Caris Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Caris Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
